Authors: Rupert D Holms.
There is a global problem of increasing incidence and prevalence of sexually transmitted infection (affecting more than ten percent of the world population), and there is a growing problem of drug and vaccine resistant infections: human ezrin peptide therapy presents a novel solution. This review summarizes the results of 17 clinical trials on the use of human ezrin peptide one (HEP-1 “Gepon”), a 14 amino acid adaptive immunity amplifying peptide registered as a pharmaceutical, which has been in use in the Russian Federation since 2001, for the treatment of a broad spectrum of sexually transmitted diseases caused by infections of bacteria, viruses, fungi and protozoans. HEP-1 and RepG3 (a derivative of HEP-1) have also been successfully used to treat SARS-CoV-2 infection. The high prevalence of chlamydia, candida, Trichomonas vaginalis, Herpes (HSV-1 & HSV-2), Human Papilloma Virus (HPV) are the result of pandemics of sexually transmitted infections (STIs) that are generally increasing world-wide, particularly in women. Although treatments or vaccines are available for the various infections, the current medical interventions have not significantly reduced the growing problem. Multi-drug resistant bacterial & viral strains, and increasing sexual promiscuity are adding to the problem, so new solutions are required. In the Russian Federation, human ezrin peptide therapy with HEP-1 (brand name “Gepon”) is used to treat candida, chlamydia, Trichomonas vaginalis, herpes, and HPV infection. In addition HEP-1 (Gepon) has been shown to be effective in combination with antibiotics, for the treatment of Syphilis. Ezrin peptides induce biological responses in patients to achieve the same or better treatment results than anti-biotic, anti-fungal, anti-viral and anti-protozoan pharmaceuticals, as well as enhancing adaptive protective immune responses like a vaccine. Ezrin peptides can be used as a post-infection vaccination strategy against re-infection. Human Ezrin Peptides can also overcome the rapidly growing problem of drug resistant strains of bacteria, protozoa and viruses. In addition, ezrin peptides amplify adaptive immune responses while simultaneously inhibiting expression of IL-1b, IL-6, IL-8 and TNFa, quickly supressing mucosal inflammation. Human Ezrin Peptides also stimulate fibroblasts to repair damaged tissues.
View/Download pdf